Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Demonstrated reduction in cardiac-related death by 43%, improved overall survival by 27% and reduced major bleeding complications by 39%
Subscribe to our email newsletter
The Medicines Company has reported data for HORIZONS-AMI Trial, which evaluated Angiomax for one year.
The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with Angiomax (bivalirudin) compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI).
The data, followed more than 3,000 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
HORIZONS-AMI, the trial of pharmacologic therapy to demonstrate a mortality benefit in STEMI patients undergoing PCI, showed that Angiomax reduced cardiac-related death by 43%, improved overall survival by 27% and reduced major bleeding complications by 39% compared with heparin plus a GP IIb/IIIa inhibitor.
Angiomax showed an absolute reduction of 1.7% in cardiac-related death and 1.3% in all-cause death at one year.
John Kelley, president and chief operating officer of The Medicines Company, said: The bottom line is that in this population of heart attack patients undergoing PCI, Angiomax saves lives, and the degree of that benefit is striking. These results underscore our goal: to bring to doctors critical care medicines that change clinical practice for the better.